Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06804135 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer

Study acronym: STIRR
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion date: Jan 2030 to Jan 30, 2030v5
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Primary completion date: Jan 2029 to Jan 1, 2029 · Start date changed from estimate of Oct 1, 2025 to Oct 25, 2025v4 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Primary completion date: Jan 2029 to Jan 1, 2029
    • Start date changed from estimate of Oct 1, 2025 to Oct 25, 2025
  3. Start date: Feb 2025 to Oct 1, 2025v3
  4. Study description expanded, about 1 wordv2 See this version in full on ClinicalTrials.gov ↗
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Radiotherapy result in tumor cell death by creating an immune potentiation effect, but can also lead to long lasting immune suppression. Thus the investigators hypothesize that pelvic and/or para-aortic radiotherapy for cervical cancer affects local tumor immunity as well as systemic immune response that may be instrumental for long term cancer cure. The goal of this observational study is to understand the effect of various radiotherapy dose per fraction, total dose and field volumes of radiation on systemic and tumor immune response in cervical cancer. The outcome of the study would be useful in improving the quality of radiation treatment and in reducing disease recurrence and improving survival in patients with cervical cancer.
Trial Details
NCT Number NCT06804135
Lead Sponsor Tata Memorial Hospital
Conditions Cervical Carcinoma
Enrollment 110 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov